Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Common Equity (2016 - 2025)

Historic Common Equity for Assembly Biosciences (ASMB) over the last 11 years, with Q3 2025 value amounting to $182.7 million.

  • Assembly Biosciences' Common Equity rose 60259.2% to $182.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $182.7 million, marking a year-over-year increase of 60259.2%. This contributed to the annual value of $33.4 million for FY2024, which is 1882.86% down from last year.
  • According to the latest figures from Q3 2025, Assembly Biosciences' Common Equity is $182.7 million, which was up 60259.2% from $18.1 million recorded in Q2 2025.
  • Assembly Biosciences' 5-year Common Equity high stood at $247.2 million for Q1 2021, and its period low was $18.1 million during Q2 2025.
  • Its 5-year average for Common Equity is $99.5 million, with a median of $70.3 million in 2023.
  • Per our database at Business Quant, Assembly Biosciences' Common Equity plummeted by 5926.53% in 2023 and then soared by 60259.2% in 2025.
  • Assembly Biosciences' Common Equity (Quarter) stood at $168.9 million in 2021, then plummeted by 51.07% to $82.7 million in 2022, then plummeted by 50.28% to $41.1 million in 2023, then fell by 18.83% to $33.4 million in 2024, then skyrocketed by 447.66% to $182.7 million in 2025.
  • Its last three reported values are $182.7 million in Q3 2025, $18.1 million for Q2 2025, and $27.1 million during Q1 2025.